No Alarm At Almirall Despite Stake Sale
Pipeline Progressing Well
Shares in the Spanish dermatology specialist have slipped as the majority shareholder sold a 6.3% stake. However, sales of its psoriasis and acne drugs, plus some promising late-stage assets, suggest Almirall is in rude health.
